https://scholars.lib.ntu.edu.tw/handle/123456789/568957
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Hsu T.-C. | en_US |
dc.contributor.author | CHI-CHUAN WANG | en_US |
dc.creator | Hsu T.-C.;Chi-Chuan Wang | - |
dc.date.accessioned | 2021-07-05T01:12:19Z | - |
dc.date.available | 2021-07-05T01:12:19Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 20426305 | - |
dc.identifier.uri | 2-s2.0-85059096340 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/568957 | - |
dc.description.abstract | Aim: Oral uracil-tegafur/leucovorin (UFT/LV) and intravenous 5-fluorouracil (FU)/LV are common adjuvant therapies for Stages II and III colorectal cancer. This study aims to determine the most cost-effective treatment alternative between UFT/LV and 5-FU/LV in Stages II and III colorectal cancer from Taiwan's National Health Insurance perspective. Patients & methods: The costs were referenced directly from the National Health Insurance reimbursement price. Chemotherapy regimen considered for the cost analysis calculation was adapted from NSABP-C-06 study, and, a time saving calculation was also included. In addition, we compare the treatment outcome. Result: A total cost saving of US$3620.80-$3709.16 per patient per treatment was achieved with the UFT/LV treatment. UFT/LV provides the comparable outcome to 5-FU/LV. Conclusion: UFT/LV was the more cost-effective treatment as adjuvant chemotherapy. ? 2019 2018 Future Medicine Ltd. | - |
dc.relation.ispartof | Journal of Comparative Effectiveness Research | - |
dc.subject | chemotherapy; cost-effective; NHI reimbursement price; oral; stage II and III colorectal cancer; UFT; uracil-tegafur | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | fluorouracil; folinic acid; UFT; ufur; antineoplastic agent; antineoplastic antimetabolite; fluorouracil; folinic acid; tegafur; uracil; vitamin B complex; Article; cancer chemotherapy; cancer staging; clinical article; colorectal cancer; controlled study; cost benefit analysis; cost control; cost effectiveness analysis; disease free survival; drug cost; hospital admission; human; multiple cycle treatment; overall survival; priority journal; Taiwan; treatment outcome; adjuvant chemotherapy; adult; aged; colorectal tumor; economics; female; health care cost; male; middle aged; multimodality cancer therapy; oral drug administration; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Cost Control; Female; Fluorouracil; Health Care Costs; Humans; Leucovorin; Male; Middle Aged; Taiwan; Tegafur; Treatment Outcome; Uracil; Vitamin B Complex | - |
dc.title | Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.2217/cer-2018-0078 | - |
dc.identifier.pmid | 30560687 | - |
dc.relation.pages | 73-79 | - |
dc.relation.journalvolume | 8 | - |
dc.relation.journalissue | 2 | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Pharmacy | - |
crisitem.author.dept | School of Pharmacy | - |
crisitem.author.orcid | 0000-0002-4597-4859 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 藥學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。